Guerbet Group

Les Pavillons-sous-Bois, France

Guerbet Group

Les Pavillons-sous-Bois, France

Time filter

Source Type

News Article | May 10, 2017
Site: www.prnewswire.com

(Logo: http://photos.prnewswire.com/prnh/20160303/792302 ) Browse 69 market data Tables and 32 Figures spread through 125 Pages and in-depth TOC on "Contrast Injector Market" Early buyers will receive 10% customization on this report. The report analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global contrast injector market is segmented on the basis of product, application, and region. On the basis of product, the contrast injector market is categorized into injector systems, consumables, and accessories. In 2016, the consumables segment is estimated to account for the largest share of the contrast injector market. This growth is mainly attributed to the recurring use of consumables in diagnostic procedures to maintain hygienic conditions. The injector systems segment is further divided into CT injector systems, MRI injector systems, and angiography injector systems. In 2016, the CT injector systems segment is expected to command the largest share of the market. The MRI injector systems segment is expected to grow at the highest CAGR during the forecast period. The consumables segment is further divided into injector heads, syringes, tubing, and other consumables (scan bags, valves, vials, and spikes). In 2016, the injector heads segment is estimated to account for the largest share of the consumables market. The injector heads segment is further categorized into single head injectors, dual head injectors, and syringeless injectors. The single head injectors segment is expected to command the largest share of the market, in 2016. The syringeless injectors segment is projected to grow at the highest CAGR during the forecast period. On the basis of application, the contrast media injector market is segmented into radiology, interventional cardiology, and interventional radiology. In 2016, the radiology segment is estimated to command the largest share of the contrast injector market. The interventional cardiology segment is expected to grow at the highest CAGR during the forecast period. Key players in the global contrast injector market include Bracco Imaging S.p.A. (Italy), Bayer HealthCare (Germany), Guerbet Group (France), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), GE Healthcare (U.S.), AngioDynamics (U.S.), Nemoto Kyorindo Co., Ltd. (Japan), Sino Medical- Device Technology Co., Ltd. (China), VIVID IMAGING (China), and Apollo RT Co., Ltd. (China). MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 10, 2017
Site: www.prnewswire.co.uk

(Logo: http://photos.prnewswire.com/prnh/20160303/792302 ) Browse 69 market data Tables and 32 Figures spread through 125 Pages and in-depth TOC on "Contrast Injector Market" Early buyers will receive 10% customization on this report. The report analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global contrast injector market is segmented on the basis of product, application, and region. On the basis of product, the contrast injector market is categorized into injector systems, consumables, and accessories. In 2016, the consumables segment is estimated to account for the largest share of the contrast injector market. This growth is mainly attributed to the recurring use of consumables in diagnostic procedures to maintain hygienic conditions. The injector systems segment is further divided into CT injector systems, MRI injector systems, and angiography injector systems. In 2016, the CT injector systems segment is expected to command the largest share of the market. The MRI injector systems segment is expected to grow at the highest CAGR during the forecast period. The consumables segment is further divided into injector heads, syringes, tubing, and other consumables (scan bags, valves, vials, and spikes). In 2016, the injector heads segment is estimated to account for the largest share of the consumables market. The injector heads segment is further categorized into single head injectors, dual head injectors, and syringeless injectors. The single head injectors segment is expected to command the largest share of the market, in 2016. The syringeless injectors segment is projected to grow at the highest CAGR during the forecast period. On the basis of application, the contrast media injector market is segmented into radiology, interventional cardiology, and interventional radiology. In 2016, the radiology segment is estimated to command the largest share of the contrast injector market. The interventional cardiology segment is expected to grow at the highest CAGR during the forecast period. Key players in the global contrast injector market include Bracco Imaging S.p.A. (Italy), Bayer HealthCare (Germany), Guerbet Group (France), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), GE Healthcare (U.S.), AngioDynamics (U.S.), Nemoto Kyorindo Co., Ltd. (Japan), Sino Medical- Device Technology Co., Ltd. (China), VIVID IMAGING (China), and Apollo RT Co., Ltd. (China). MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


Daldrup-Link H.E.,Stanford University | Golovko D.,University of Massachusetts Medical School | Ruffell B.,University of California at San Francisco | DeNardo D.G.,University of California at San Francisco | And 7 more authors.
Clinical Cancer Research | Year: 2011

Purpose: The presence of tumor-associated macrophages (TAM) in breast cancer correlates strongly with poor outcome. The purpose of this study was to develop a clinically applicable, noninvasive diagnostic assay for selective targeting and visualization of TAMs in breast cancer, based on magnetic resonanceI and clinically applicable iron oxide nanoparticles. Experimental Design: F4/80-negative mammary carcinoma cells and F4/80-positive TAMs were incubated with iron oxide nanoparticles and were compared with respect to magnetic resonance signal changes and iron uptake. MMTV-PyMT transgenic mice harboring mammary carcinomas underwent nanoparticle-enhanced magnetic resonance imaging (MRI) up to 1 hour and 24 hours after injection.The tumor enhancement on MRIs was correlated with the presence and location of TAMs and nanoparticles by confocal microscopy. Results: In vitro studies revealed that iron oxide nanoparticles are preferentially phagocytosed by TAMs but not by malignant tumor cells. In vivo, all tumors showed an initial contrast agent perfusion on immediate postcontrast MRIs with gradual transendothelial leakage into the tumor interstitium. Twenty-four hours after injection, all tumors showed a persistent signal decline on MRIs. TAM depletion via αCSF1 monoclonal antibodies led to significant inhibition of tumor nanoparticle enhancement. Detection of iron using 3,3′-diaminobenzidine-enhanced Prussian Blue staining, combined with immunodetection of CD68, localized iron oxide nanoparticles to TAMs, showing that the signal effects on delayed MRIs were largely due to TAM-mediated uptake of contrast agent. Conclusion: These data indicate that tumor enhancement with clinically applicable iron oxide nanoparticles may serve as a new biomarker for long-term prognosis, related treatment decisions, and the evaluation of new immune-targeted therapies. ©2011 AACR.


Sigovan M.,University of Lyon | Sigovan M.,University of California at San Francisco | Kaye E.,Stanford University | Lancelot E.,GUERBET Group | And 5 more authors.
Investigative Radiology | Year: 2012

OBJECTIVES: The renin-angiotensin system and local phagocytic activity play a major role in atherosclerotic plaque development. Treatment with irbesartan, an antagonist of angiotensin II receptor, can decrease atherosclerotic lesion formation. Iron oxide-enhanced magnetic resonance imaging (MRI) can be successfully used to evaluate the phagocytic activity in the atherosclerotic plaque in mice. In this study, we used 2 iron oxide-enhanced MRI strategies, in vivo labeling by injection of iron oxide particles and injection of in vitro labeled macrophages, to investigate the effect of irbesartan on both atherosclerotic plaque size and macrophage content in apolipoprotein (Apo) E-deficient mice. MATERIALS AND METHODS: ApoE-/-female mice (C57BL/6 background; Charles-River, France) were divided into 2 groups (irbesartan treated [TG] or not treated [NTG]) and started on a high-fat diet (Harlan TD88137 Western Diet, 21% fat, 0.2% cholesterol). Animals underwent magnetic resonance examinations on a 7-T scanner at baseline and at 14 and 28 weeks of treatment. At each time point, 2 MRI sessions were performed, before and 48 hours after administration of an iron oxide agent (P904; Guerbet, France) or magnetically labeled macrophages (MΦΦ). At the end of the follow-up, blood samples were taken for plasma lipid dosing and aorta samples for histology. The study was approved by the animal experimentation ethic committee of our institution.Vessel wall area measurements were performed on high-resolution spin echo transverse images. Multiecho gradient echo images acquired with the same geometry were used to calculate T2* maps of the vessel wall using a pixel-by-pixel monoexponential fit. Irbesartan effect on vessel wall area over time was assessed using a factorial analysis of variance test. T2* values of the vessel wall at pre-and post-ultrasmall superparamagnetic iron oxide (USPIO) administration were analyzed with a 1-way analysis of variance test with Bonferroni post hoc. RESULTS: Irbesartan treatment resulted in significantly smaller vessel wall areas at 28 weeks of treatment (P = 0.04). Postinjection values varied significantly over time for both the NTG-P904 (P = 0.02) and the TG-P904 (P = 0.01) groups. Furthermore, when comparing the TG-P904 with the NTG-P904 group at 28 weeks of treatment, a significant difference was obtained for both pre-and post-USPIO administration values (P = 0.01). In the labeled-macrophage group, postinjection T2* values were smaller than the preinjection ones for the NTG animals at 14 weeks of treatment. No T2* changes were observed in the TG-MΦ group.The difference between pre-and post-USPIO administration T2* values (ΔT2*) was significantly smaller in the TG-P904 group compared with the NTG-P904 group at 28 weeks of treatment. At this point, a good correlation (R = 0.7, P = 0.03) was found between the ΔT2* values in the P904 imaging group and the macrophage-covered area by immunohistological analysis. CONCLUSIONS: The present study illustrates an MRI follow-up of intraplaque macrophages using in vivo labeling by iron oxide particle injection and macrophage injection after in vitro USPIO labeling in the assessment of a therapeutic effect in a mouse model of atherosclerosis. Even though in vivo labeling is not fully specific of macrophage uptake, it enabled the detection of a treatment-related reduction in the macrophage content of atherosclerotic plaques in ApoE-/-mice. ©2012 by Lippincott Williams & Wilkins.


News Article | November 7, 2016
Site: www.prweb.com

On November 12, 2016 more than 20 employees of the Guerbet Group, a France-based global specialist in contrast agents and solutions for medical imaging, will gather to plant 90 trees in Franz Park and Francis Slay Park in celebration of the company’s 90th anniversary—and its first year spent in St. Louis. In 2015, Guerbet opened the America’s Shared Service Center in St Louis. The planting of the trees is symbolic of the Group’s roots and growth, from the early days of medical imaging to its most recent applications, and its plans for a bright future in St. Louis. The St. Louis office started in 2015, under the entity named Liebel-Flarsheim, with 70 employees transferred from the contrast media and delivery system business acquired from Mallinckrodt. It is now the company’s most important Shared Service Center in the Guerbet organization with 130 employees. Employees at the St. Louis office work in Finance, IT, and Supply Chain/Customer Service for North and South America, in addition to managing some of the company’s operations worldwide. “The tree planting ceremony is an opportunity to thank our staff and share with our partners the values that contribute to Guerbet’s success,” said Bruno Bonnemain, St Louis Site Director. “These ideals include innovation, respect for all the stakeholders in our ecosystem and the long-term development vision, and the integration of employees with different cultures and ways of working.” Guerbet is an international group, currently employing 2,600 people worldwide. Although 1,000 of the company’s employees are based in France, eighty-five percent of the company’s sales are achieved outside of France. The company’s growth drivers include being contrast agents for MRIs, contrast agents for X-ray imaging, Interventional Radiology, and Theranostics, and Imaging Solutions and Services, including medical devices such as injectors. The Group doubled in size in 2015 following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business. Plans to expand the St. Louis office are underway. “I would like to thank the staff of the St. Louis site for their strong contribution to the success of Guerbet, which is experiencing a key period in its history,” said Yves L’Epine, Guerbet CEO. “We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging. More than ever, offering indispensable solutions for diagnostic and interventional imaging all over the world is paramount. Faced with the challenges of aging, the development of chronic diseases, and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of predictive capabilities to benefit patients.” About Guerbet Guerbet is a pioneer in the contrast agent field, with 90 years’ experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €789 million in pro forma revenue in 2015. For more information about Guerbet, please visit http://www.guerbet.com.


Segers F.M.E.,Leiden University | Den Adel B.,Leiden University | Bot I.,Leiden University | Van Der Graaf L.M.,Leiden University | And 10 more authors.
Arteriosclerosis, Thrombosis, and Vascular Biology | Year: 2013

OBJECTIVE - : In search of molecular imaging modalities for specific detection of inflammatory atherosclerotic plaques, we explored the potential of targeting scavenger receptor-AI (SR-AI), which is highly expressed by lesional macrophages and linked to effective internalization machinery. APPROACH AND RESULTS - : Ultrasmall superparamagnetic iron oxide particles were conjugated to a peptidic SR-AI ligand (0.371 mol Fe/L and 0.018 mol PP1/L). In vitro incubation of human or murine macrophages with SR-AI-targeted USPIO led to significantly higher iron uptake in vitro than with nontargeted USPIO, as judged by quantitative atomic absorption spectroscopy and Perl's staining. Incremental uptake was strictly mediated by SRs. SR-AI-targeted USPIO displayed accelerated plasma decay and a 3.5-fold increase (P=0.01) in atherosclerotic plaque accumulation on intravenous injection into apolipoprotein E-deficient mice compared with nontargeted USPIO. In addition, atherosclerotic humanized LDLr-/- chimeras with leukocyte expression of human SR-AI showed a significant improvement in contrast-to-noise ratio (2.7-fold; P=0.003) in the atherosclerotic aortic arch plaques 24 hours after injection of SR-AI-targeted USPIO compared with chimeras with leukocyte SR-AI deficiency. CONCLUSIONS - : Collectively, our data provide several lines of evidence that SR-AI-targeted molecular imaging of USPIO-based contrast agents holds great promise for in situ detection of inflammatory plaques in manifest atherosclerosis. © 2013 American Heart Association, Inc.


News Article | October 31, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of Contrast Media in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering  Bayer HealthCare  GE Healthcare  Guerbet Group  Bracco Imaging S.p.A.  Lantheus Medical Imaging  nanoPET Pharma GmbH  CMC Contrast AB  Daiichi Sankyo  Subhra Pharma Private Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Contrast Media in these regions, from 2011 to 2021 (forecast), like  USA  China  Europe  Japan  India  Southeast Asia Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into  Iodinated  Gadolinium  Barium  Microbubble  Others Split by applications, this report focuses on sales, market share and growth rate of Contrast Media in each application, can be divided into  Radiology  Interventional Radiology  Interventional Cardiology  Others Global Contrast Media Sales Market Report 2016  1 Contrast Media Overview  1.1 Product Overview and Scope of Contrast Media  1.2 Classification of Contrast Media  1.2.1 Iodinated  1.2.2 Gadolinium  1.2.3 Barium  1.2.4 Microbubble  1.2.5 Others  1.3 Application of Contrast Media  1.3.1 Radiology  1.3.2 Interventional Radiology  1.3.3 Interventional Cardiology  1.3.4 Others  1.4 Contrast Media Market by Regions  1.4.1 USA Status and Prospect (2011-2021)  1.4.2 China Status and Prospect (2011-2021)  1.4.3 Europe Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 India Status and Prospect (2011-2021)  1.4.6 Southeast Asia Status and Prospect (2011-2021)  1.5 Global Market Size (Value and Volume) of Contrast Media (2011-2021)  1.5.1 Global Contrast Media Sales and Growth Rate (2011-2021)  1.5.2 Global Contrast Media Revenue and Growth Rate (2011-2021) 9 Global Contrast Media Manufacturers Analysis  9.1 Bayer HealthCare  9.1.1 Company Basic Information, Manufacturing Base and Competitors  9.1.2 Contrast Media Product Type, Application and Specification  9.1.2.1 Type I  9.1.2.2 Type II  9.1.3 Bayer HealthCare Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.1.4 Main Business/Business Overview  9.2 GE Healthcare  9.2.1 Company Basic Information, Manufacturing Base and Competitors  9.2.2 124 Product Type, Application and Specification  9.2.2.1 Type I  9.2.2.2 Type II  9.2.3 GE Healthcare Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.2.4 Main Business/Business Overview  9.3 Guerbet Group  9.3.1 Company Basic Information, Manufacturing Base and Competitors  9.3.2 147 Product Type, Application and Specification  9.3.2.1 Type I  9.3.2.2 Type II  9.3.3 Guerbet Group Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.3.4 Main Business/Business Overview  9.4 Bracco Imaging S.p.A.  9.4.1 Company Basic Information, Manufacturing Base and Competitors  9.4.2 Oct Product Type, Application and Specification  9.4.2.1 Type I  9.4.2.2 Type II  9.4.3 Bracco Imaging S.p.A. Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.4.4 Main Business/Business Overview  9.5 Lantheus Medical Imaging  9.5.1 Company Basic Information, Manufacturing Base and Competitors  9.5.2 Product Type, Application and Specification  9.5.2.1 Type I  9.5.2.2 Type II  9.5.3 Lantheus Medical Imaging Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.5.4 Main Business/Business Overview  9.6 nanoPET Pharma GmbH  9.6.1 Company Basic Information, Manufacturing Base and Competitors  9.6.2 Million USD Product Type, Application and Specification  9.6.2.1 Type I  9.6.2.2 Type II  9.6.3 nanoPET Pharma GmbH Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.6.4 Main Business/Business Overview  9.7 CMC Contrast AB  9.7.1 Company Basic Information, Manufacturing Base and Competitors  9.7.2 Pharma & Healthcare Product Type, Application and Specification  9.7.2.1 Type I  9.7.2.2 Type II  9.7.3 CMC Contrast AB Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.7.4 Main Business/Business Overview  9.8 Daiichi Sankyo  9.8.1 Company Basic Information, Manufacturing Base and Competitors  9.8.2 Product Type, Application and Specification  9.8.2.1 Type I  9.8.2.2 Type II  9.8.3 Daiichi Sankyo Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.8.4 Main Business/Business Overview  9.9 Subhra Pharma Private  9.9.1 Company Basic Information, Manufacturing Base and Competitors  9.9.2 Product Type, Application and Specification  9.9.2.1 Type I  9.9.2.2 Type II  9.9.3 Subhra Pharma Private Contrast Media Sales, Revenue, Price and Gross Margin (2011-2016)  9.9.4 Main Business/Business Overview


News Article | November 2, 2016
Site: marketersmedia.com

— The report "Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global contrast media/contrast agents market has been segmented on the basis of type, route of administration, indication, procedure, application, and region. Based on type, the contrast media/contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, barium-based contrast media, and microbubble contrast media. In 2016, the iodinated contrast media segment is estimated to account for the largest share of the contrast media/contrast agents market, by type. However, the microbubble contrast media segment is expected to grow at the highest CAGR during the forecast period. The high growth of the microbubble segment can be attributed to the large number of on-going academic researches that are exploring various attributes of microbubbles in off-label indications for diagnosis as well as drug delivery. Based on procedure, the contrast media/contrast agents market is segmented into X-ray/computed tomography, magnetic resonance imaging, and ultrasound. Based on route of administration, the contrast media/contrast agents market has been segmented into oral, injectable, rectal, and urethral routes. In 2016, the injectable segment is expected to account for the largest share of the contrast media/contrast agents market. Growth in the injectable contrast media segment can be attributed to advancements in CT and MRI imaging technologies, which majorly use injectable contrast media. Based on indication, the contrast media/contrast agentsmarket is segmented into cardiovascular disorders, oncology, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. In 2016, the cardiovascular disorders segment is estimated to account for the largest share of the global contrast media/contrast agentsmarket. Improvements in cardiac MRI procedures in cath labs, favorable reimbursement policies for contrast media used in cardiovascular diagnosis, and strong healthcare infrastructure in countries like the U.S., Canada, the U.K., and Germany are some of the factors driving the growth of this segment. Based on procedure, the global contrast media/contrast agents market is segmented into X-ray/CT, MRI, and ultrasound. In 2016, the X-ray/CT segment is expected to account for the largest share of the contrast media/contrast agents market. However, the ultrasound segment is expected to register the highest CAGR during the forecast period. Development of microbubble contrast media for ultrasound, and large number of approvals for ultrasound contrast media in major markets such as the U.S., Europe, and Japan are some of the key factors driving the growth of this segment. Based on application, the global contrast media/contrast agents market has been segmented into radiology, interventional radiology, and interventional cardiology. In 2016, the radiology segment is estimated to account for the largest share of the contrast media/contrast agents market. The large share of this segment can be attributed to the growing number of diagnostic procedures/centers, coupled with the increasing disease burden on countries. North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global contrast media/contrast agents market. In 2016, North America is estimated to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the European market is expected to grow at the highest CAGR during the forecast period, and will also serve as a revenue pocket for companies offering contrast media/contrast agents in the near future. The prominent players in the global contrast media/contrast agents market include Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), and Bracco Imaging S.p.A. (Italy). These companies hold a dominant position in the contrast media/contrast agents market mainly due to their well-established presence in the field of genomics, presence in over 50 countries, high R&D investments, and strong sales and distribution force. Other players operating in this market include Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India). For more information, please visit http://www.marketsandmarkets.com/requestsample.asp?id=911


The global contrast media market is projected to reach USD 5.44 Billion by 2021 from USD 4.46 Billion in 2016 growing at a CAGR of 4.1% during the forecast period. This growth can be attributed to factors such as increasing approvals for contrast agents and increase in the number of public and private diagnostic centers to improve diagnostic imaging services are driving the demand of various diagnostic imaging modalities. Moreover, strong product pipelines of the market players, coupled with the increasing research studies regarding applications of various contrast agents, are expected to drive the market in the near future. Complete report on Contrast Media Market spread across 159 Pages, Profiling 11 Companies and Supported with 77 Tables and 41 Figures is now available at http://www.rnrmarketresearch.com/contrast-mediacontrast-agents-market-by-product-iodinated-gadolinium-barium-by-technique-x-ray-ct-mri-cath-lab-ultrasound-by-application-radiology-interventional-radiology-interven-market-report.html . Factors such as increasing approvals for contrast agents and increase in the number of public and private diagnostic centers to improve diagnostic imaging services are driving the demand of various diagnostic imaging modalities. Moreover, strong product pipelines of the market players, coupled with the increasing research studies regarding applications of various contrast agents, are expected to create opportunities for market growth in the near future. However side effects, adverse and allergic reactions associated with contrast agents are restraining the growth of the market to a certain extent. North America, Europe, Asia-Pacific, and Rest of the World (RoW) are the regions considered for a geographic analysis of the global market. In 2016, North America is estimated to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the Europe market is expected to grow at the highest CAGR during the forecast period, and also serve as a revenue pocket for companies offering contrast media/contrast agents in the near future. Interested in this report, Get sample copy of this research now In 2016, the iodinated contrast media segment expected to account for the largest share of the global contrast media market, among type of contrast media; the injectable contrast media segment is expected to account for the largest share of the global contrast media agents market, among the routes of administration; the X-ray/CT segment is expected to dominate the global contrast media market, among procedures; the cardiovascular disorders segment is expected to account for the largest share of the global contrast media market, among indications; and the radiology segment is expected to dominate the contrast media market, among applications. Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A. (Italy) in 2015. These companies are dominant in the market mainly due to their well-established presence in the field of contrast media, presence in over 50 countries, high R&D investments, and strong sales and distribution force. While the other players includes Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), and Subhra Pharma Private Limited (India). Click now for more information on this research of “Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium, & Microbubble), Procedure (X-Ray/CT, MRI, & Ultrasound) & Application (Radiology, Interventional Radiology, & Interventional Cardiology) - Global Forecasts to 2021” report @ http://www.rnrmarketresearch.com/contacts/discount?rname=66961 . The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies such as product approvals, agreements, collaborations, contract, and partnerships; expansions; and other strategies (divestment, grant, insurance coverage approval and acquisition) to increase their market shares and establish a strong foothold in the contrast media market. Based on region, the global contrast media market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is estimated to account for the largest share, followed by Europe and Asia-Pacific. However, the European market is expected to grow at the highest CAGR during the forecast period, and will also serve as a revenue pocket for companies offering contrast media/contrast agents in the near future. The high growth in this region can be attributed to the increasing research & development investments by market players, increasing incidence and prevalence of cancer, and increasing number of MRI and CT scanners. Explore more reports on Biotechnology at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology .


Sigovan M.,CNRS Research Center for Image Acquisition and Processing for Health | Bessaad A.,CNRS Research Center for Image Acquisition and Processing for Health | Alsaid H.,CNRS Research Center for Image Acquisition and Processing for Health | Lancelot E.,GUERBET Group | And 6 more authors.
Investigative Radiology | Year: 2010

Objective: Inflammation within atherosclerotic lesions increases the risk for plaque rupture and thrombosis. A functional approach to plaque analysis is the intravenous administration of ultrasmall superparamagnetic particles of iron oxide (USPIO) that enables visualization of macrophages residing in the plaques. In this study, we sought to characterize the age-related inflammatory status associated with atherosclerosis lesion progression in ApoE-/- mice using USPIO-enhanced magnetic resonance imaging (MRI). Materials and Methods: A total of 24 ApoE mice were divided in 4 groups (N = 6) and were given a high cholesterol diet from 6 weeks of age to the end of the protocol. One group per MR time point was investigated at 10, 16, 24, and 34 weeks of age. Each MR examination was performed on a 4.7 T scanner and consisted of baseline and 48 hours post-USPIO administration imaging sessions. P904, a USPIO contrast agent (Guerbet, Paris, France) with a potential for plaque macrophage targeting, was used.Vessel wall area measurements were performed on high resolution spin echo transverse images. Multi-echo gradient-echo images acquired with the same geometry were used to calculate T2* maps of the vessel wall using a pixel-by-pixel monoexponential fit. A one-way analysis of variance was performed to characterize the temporal variation of vessel wall area, susceptibility artifact area, baseline, and post-USPIO T2* values. MR measurements were correlated with the histologic findings. Results: A significant increase was found in the aortic wall area from 1.4 ± 0.2 at 10 weeks to 2.0 ± 0.3 mm at 34 weeks of age (P < 0.05). Concerning the post-USPIO MRI, signal loss regions, with patterns spanning from focal to the complete disappearance of the vessel wall, were observed on all postcontrast images. A significant increase in the size of the susceptibility artifact was observed from 0.5 ± 0.2 to 2.4 ± 1.0 at 24 weeks (P < 0.05) and to 2.0 ± 0.9 mm at 34 weeks (P < 0.05).The T2* values calculated on the 48 hours post-USPIO images were shorter compared with baseline. The decrease was 34% ± 16% at 10 weeks, 57% ± 11% at 16 weeks, 57% ± 16% at 24 weeks, and 48% ± 13% at 34 weeks.The Pearson's correlation test between measurement of aortic wall area performed on both MR images and histologic analysis showed a statistically significant correlation (r = 0.695 and P < 0.05). A correlation was also obtained between the signal loss area and the macrophages covered area (r = 0.68 and P < 0.05). Conclusions: This study demonstrated the feasibility of USPIO-enhanced MRI in assessing the inflammatory status related to the temporal progression of the atherosclerosis plaque in ApoE transgenic mice model of atherosclerosis. In our experimental conditions, the vascular inflammation peak, for the ApoE-/-mice feeding high-fat/high-cholesterol diet is measured between 16 and 24 weeks of age. Copyright © 2010 by Lippincott Williams and Wilkins.

Loading Guerbet Group collaborators
Loading Guerbet Group collaborators